Nanjing King Friend
Nanjing King Friend Pharmaceutical Co., Ltd., commonly referred to as King Friend, is a prominent player in the pharmaceutical industry, headquartered in Nanjing, China. Established in 2002, the company has made significant strides in the development and production of high-quality pharmaceutical intermediates and active pharmaceutical ingredients (APIs), catering to both domestic and international markets. With a strong focus on research and development, King Friend has built a reputation for its innovative solutions in the fields of oncology, cardiovascular health, and anti-infectives. The company’s commitment to quality and compliance has positioned it as a trusted partner for pharmaceutical companies worldwide. Notable achievements include various certifications and partnerships that underscore its market leadership and dedication to excellence in the pharmaceutical sector.
DitchCarbon Score
How does Nanjing King Friend's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nanjing King Friend's score of 16 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nanjing King Friend's reported carbon emissions
In 2023, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd reported total carbon emissions of approximately 1,628,340 kg CO2e. This figure includes Scope 1 emissions of about 20,290 kg CO2e, Scope 2 emissions of approximately 1,596,280 kg CO2e, and Scope 3 emissions of around 11,770 kg CO2e. Comparatively, in 2022, the company’s total emissions were about 1,739,490 kg CO2e, with Scope 1 at 76,660 kg CO2e, Scope 2 at 1,648,730 kg CO2e, and Scope 3 at 14,100 kg CO2e. This indicates a reduction in total emissions of approximately 111,150 kg CO2e from 2022 to 2023. Nanjing King-Friend has committed to near-term climate targets, although specific reduction targets have not been disclosed. The company has not yet committed to a net-zero target. As a player in the pharmaceuticals, biotechnology, and life sciences sector, Nanjing King-Friend is positioned within an industry increasingly focused on sustainability and carbon footprint reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 76,660 | 00,000 |
| Scope 2 | 1,648,730 | 0,000,000 |
| Scope 3 | 14,100 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nanjing King Friend is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
